HighTower Advisors’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

HighTower Advisors’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-138,988	Closed	-$1.39M	–	3449
2021 Q1	$1.39M	Buy	+138,988	New	+$1.44M	﹤0.01%	1374

Other funds holding PRDS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SRCM

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

MAMNY

Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return

HighTower Advisors's PRDS Position: Q2 2021 in Review

HighTower Advisors sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2021, closing a stake of 138,988 shares — an estimated $1.39M sold.

HighTower Advisors first reported a position in PRDS in Q1 2021 and held it in 1 quarter. The position peaked at $1.39M in Q1 2021. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2021.

HighTower Advisors reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
HighTower Advisors sold 138,988 Pardes Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $1.39M.
HighTower Advisors first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
HighTower Advisors's Pardes Biosciences, Inc. Common Stock position peaked at $1.39M in Q1 2021.
69 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.